Edelfosine

Edelfosine (ET-18-O-CH3; 1-octadecyl-2-O-methyl-glycero-3-phosphocholine) is a synthetic alkyl-lysophospholipid (ALP). It has antineoplastic (anti-cancer) effects. Like all ALPs, it incorporates into the cell membrane and does not target the DNA. In many tumor cells, it causes selective apoptosis, sparing healthy cells. Edelfosine can activate the Fas/CD95 cell death receptor, can inhibit the MAPK/ERK mitogenic pathway and the Akt/protein kinase B (PKB) survival pathway. Aside from these plasma-level effects, edelfosine also affects gene expression by modulating the expression and activity of transcription factors. It has immune modulating properties. These characteristics cause edelfosine also to affect HIV, parasitic, and autoimmune diseases. It can complement classic anti-cancer drugs such as cisplatin. It can be administered orally, intraperitoneally (IP) and intravenously (IV). Edelfosine and other ALPs can be used for purging residual leukemic cells from bone marrow transplants. It is an analog of miltefosine and perifosine. (Wikipedia).